Brokers Offer Predictions for ConforMIS Inc.’s Q3 2016 Earnings (CFMS)
ConforMIS Inc. (NASDAQ:CFMS) – Investment analysts at SunTrust Banks issued their Q3 2016 earnings per share (EPS) estimates for shares of ConforMIS in a report issued on Monday. SunTrust Banks analyst B. Nudell expects that the firm will post earnings per share of ($0.34) for the quarter. SunTrust Banks has a “Buy” rating and a $14.00 price objective on the stock. SunTrust Banks also issued estimates for ConforMIS’s Q4 2016 earnings at ($0.30) EPS, FY2016 earnings at ($1.35) EPS, Q1 2017 earnings at ($0.37) EPS, Q2 2017 earnings at ($0.35) EPS, Q3 2017 earnings at ($0.29) EPS, Q4 2017 earnings at ($0.22) EPS, FY2017 earnings at ($1.20) EPS, FY2018 earnings at ($0.99) EPS, FY2019 earnings at ($0.84) EPS and FY2020 earnings at ($0.55) EPS.
ConforMIS (NASDAQ:CFMS) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.01. ConforMIS had a negative return on equity of 45.30% and a negative net margin of 84.33%. The firm earned $19.30 million during the quarter, compared to analysts’ expectations of $18.02 million. During the same quarter last year, the firm posted ($2.51) earnings per share. The company’s revenue for the quarter was up .5% compared to the same quarter last year.
A number of other equities analysts have also recently issued reports on CFMS. Zacks Investment Research upgraded ConforMIS from a “sell” rating to a “hold” rating in a report on Wednesday, June 1st. Oppenheimer Holdings Inc. increased their target price on ConforMIS from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Tuesday, August 9th. JPMorgan Chase & Co. dropped their target price on ConforMIS from $11.00 to $8.00 and set a “neutral” rating for the company in a report on Tuesday, August 9th. Finally, B. Riley initiated coverage on ConforMIS in a report on Thursday, September 15th. They set a “buy” rating and a $13.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $14.86.
Shares of ConforMIS (NASDAQ:CFMS) opened at 9.79 on Wednesday. ConforMIS has a 52 week low of $4.80 and a 52 week high of $23.62. The firm has a 50-day moving average price of $8.37 and a 200-day moving average price of $8.81. The firm’s market cap is $412.42 million.
In other ConforMIS news, Director Kenneth P. Fallon III sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $8.44, for a total transaction of $33,760.00. Following the completion of the transaction, the director now owns 92,222 shares of the company’s stock, valued at approximately $778,353.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Daniel Steines sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $9.09, for a total value of $272,700.00. Following the transaction, the insider now directly owns 245,213 shares of the company’s stock, valued at approximately $2,228,986.17. The disclosure for this sale can be found here. Company insiders own 9.20% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Institutional Trust Company N.A. raised its position in ConforMIS by 0.9% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 272,339 shares of the company’s stock worth $2,928,000 after buying an additional 2,347 shares during the last quarter. Geode Capital Management LLC raised its position in shares of ConforMIS by 15.1% in the first quarter. Geode Capital Management LLC now owns 77,877 shares of the company’s stock valued at $837,000 after buying an additional 10,235 shares in the last quarter. LPL Financial LLC purchased a new position in shares of ConforMIS during the first quarter valued at about $145,000. American International Group Inc. raised its position in shares of ConforMIS by 242.6% in the second quarter. American International Group Inc. now owns 20,584 shares of the company’s stock valued at $144,000 after buying an additional 14,575 shares in the last quarter. Finally, Raymond James & Associates purchased a new position in shares of ConforMIS during the second quarter valued at about $113,000. 41.38% of the stock is owned by institutional investors and hedge funds.
ConforMIS Company Profile
ConforMIS, Inc is a medical technology company that uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants. The Company’s products include iTotal CR, which is the cruciate-retaining, customized total knee replacement system to restore the natural shape of a patient’s knee; iTotal PS, which is the posterior cruciate ligament substituting, or posterior-stabilized, customized total knee replacement product to restore the natural shape of a patient’s knee; iDuo, which is the customized bicompartmental knee replacement system, and iUni, which is the customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee.
Receive News & Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.